Current position

Ray Dalio’s Procter & Gamble (PG) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2006Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares6.82MHighest verified quarter-end share count
Quarters reported37Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Procter & Gamble in Q4 2006. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 137.72K shares. The latest verified filing showed: Sold 12.8% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 12.8% of the position−20.18K shares · 137.72K shares remained
Filing context

Quarter-end price $146.64 · Estimated holding basis $143.62

Q1 2026
Sold 14.8% of the position−27.45K shares · 157.91K shares remained
Filing context

Quarter-end price $144.44 · Estimated holding basis $143.62

Q4 2025
Bought 31.0% more+43.90K shares · 185.35K shares reported after the change
Filing context

Quarter-end price $143.31 · Estimated holding basis $143.62

Q3 2025
Bought 6.4% more+8.55K shares · 141.46K shares reported after the change
Filing context

Quarter-end price $153.65 · Estimated holding basis $143.72

Q2 2025
Sold 28.0% of the position−51.81K shares · 132.91K shares remained
Filing context

Quarter-end price $159.32 · Estimated holding basis $143.08

Q1 2025
Sold 58.0% of the position−254.89K shares · 184.72K shares remained
Filing context

Quarter-end price $170.42 · Estimated holding basis $143.08

Portfolio importance

How important is Procter & Gamble in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#204of 997 reported positions
Peak portfolio weight4.9%Q4 2021
Best historical rank#1Q2 2022
At peak importanceQ4 2021
PG
4.9%
Largest holding
5.2%
Cross-investor discovery

Who else owns Procter & Gamble?

Also reported by 3 other tracked investors in their latest verified filings.

Terry SmithFundsmith LLP
PG4.4% of reported portfolio
Joel GreenblattGotham Asset Management
PG0.1% of reported portfolio
Tom RussoGardner Russo & Quinn · formerly Gardner Russo & Gardner
PG0.0% of reported portfolio
Explore Procter & Gamble across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$146.392026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$146.64Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$143.62Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Procter & Gamble stock page →

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.